The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Comparing atezolizumab & bevacizumab with STRIDE in advanced HCC
Federica Lo Prinzi, MD, Campus Bio-Medico University Hospital Foundation, Rome, Italy, comments on a retrospective real-world analysis comparing atezolizumab plus bevacizumab with tremelimumab and durvalumab (STRIDE) as first-line therapy for advanced hepatocellular carcinoma (HCC). Using matched patient cohorts, the study found no significant difference in overall survival between the two treatment strategies, suggesting both regimens represent valid options in this setting. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Our analysis is about the comparison of these two first-line therapies in advanced hepatocellular carcinoma. The result of our analysis shows that both of these first-line therapies are equally valid for these patients. In the recent literature, our absence of this type of study and we with this result could link this gap and so we think it’s very important for our patients...
Our analysis is about the comparison of these two first-line therapies in advanced hepatocellular carcinoma. The result of our analysis shows that both of these first-line therapies are equally valid for these patients. In the recent literature, our absence of this type of study and we with this result could link this gap and so we think it’s very important for our patients. It’s very important the discussion between physician and patients because we could decide on both therapies, Durvalumab and Tremelimumab or Bevacizumab and Atezolizumab because they are equally valid but it’s important to discuss with the patient or caregiver when it’s available and decide about the patient’s characteristics that are associated with the treatment, the cost, the benefit of treatment, and the goal of treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
